<?xml version="1.0" encoding="ISO-8859-1"?><article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
<front>
<journal-meta>
<journal-id>1699-714X</journal-id>
<journal-title><![CDATA[Revista de la OFIL ]]></journal-title>
<abbrev-journal-title><![CDATA[Rev. OFIL·ILAPHAR]]></abbrev-journal-title>
<issn>1699-714X</issn>
<publisher>
<publisher-name><![CDATA[Organización de Farmacéuticos Ibero-Latinoamericanos]]></publisher-name>
</publisher>
</journal-meta>
<article-meta>
<article-id>S1699-714X2021000300287</article-id>
<article-id pub-id-type="doi">10.4321/s1699-714x2021000300007</article-id>
<title-group>
<article-title xml:lang="es"><![CDATA[Monitorización de concentraciones plasmáticas de vancomicina en pacientes críticos de un hospital público de Córdoba, Argentina]]></article-title>
<article-title xml:lang="en"><![CDATA[Monitoring of plasma vancomycin concentrations in critically ill patients in a public hospital of Córdoba, Argentina]]></article-title>
</title-group>
<contrib-group>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Suarez]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
<xref ref-type="aff" rid="Aaf"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Maldonado]]></surname>
<given-names><![CDATA[C]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Vázquez]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Olivera]]></surname>
<given-names><![CDATA[ME]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
<xref ref-type="aff" rid="Aaf"/>
</contrib>
</contrib-group>
<aff id="Af1">
<institution><![CDATA[,Hospital Córdoba Servicio de Farmacia ]]></institution>
<addr-line><![CDATA[Córdoba ]]></addr-line>
<country>Argentina</country>
</aff>
<aff id="Af2">
<institution><![CDATA[,Hospital de Clínicas &#8220;Dr. Manuel Quíntela&#8221; Departamento de Ciencias Farmacéuticas de la Facultad de Química. Área de Biofarmacia y Terapéutica Unidad de Monitorización de Medicamentos]]></institution>
<addr-line><![CDATA[Montevideo ]]></addr-line>
<country>Uruguay</country>
</aff>
<aff id="Af3">
<institution><![CDATA[,Universidad Nacional de Córdoba Facultad de Ciencias Químicas Departamento de Ciencias Farmacéuticas]]></institution>
<addr-line><![CDATA[ ]]></addr-line>
<country>Argentina</country>
</aff>
<aff id="Af4">
<institution><![CDATA[,Universidad Nacional de Córdoba Facultad de Ciencias Químicas ]]></institution>
<addr-line><![CDATA[ ]]></addr-line>
<country>Argentina</country>
</aff>
<pub-date pub-type="pub">
<day>00</day>
<month>09</month>
<year>2021</year>
</pub-date>
<pub-date pub-type="epub">
<day>00</day>
<month>09</month>
<year>2021</year>
</pub-date>
<volume>31</volume>
<numero>3</numero>
<fpage>287</fpage>
<lpage>295</lpage>
<copyright-statement/>
<copyright-year/>
<self-uri xlink:href="http://scielo.isciii.es/scielo.php?script=sci_arttext&amp;pid=S1699-714X2021000300287&amp;lng=en&amp;nrm=iso"></self-uri><self-uri xlink:href="http://scielo.isciii.es/scielo.php?script=sci_abstract&amp;pid=S1699-714X2021000300287&amp;lng=en&amp;nrm=iso"></self-uri><self-uri xlink:href="http://scielo.isciii.es/scielo.php?script=sci_pdf&amp;pid=S1699-714X2021000300287&amp;lng=en&amp;nrm=iso"></self-uri><abstract abstract-type="short" xml:lang="es"><p><![CDATA[RESUMEN  Introducción: La monitorización de las concentraciones plasmáticas de antimicrobianos utilizados para tratar infecciones en pacientes críticos es una de las estrategias propuestas para mejorar los resultados clínicos. La monitorización de vancomicina reduce el riesgo de resistencia bacteriana y de nefrotoxicidad relacionada con altas concentraciones plasmáticas. El estudio fue realizado en un hospital público de la provincia de Córdoba, Argentina, que contiene 43 unidades críticas de atención al paciente. Aunque la indicación de vancomicina es frecuente, la solicitud de niveles plasmáticos de fármacos es inusual.  Método: El Servicio de Farmacia realizó un estudio piloto prospectivo durante 14 semanas, implementando el monitoreo de las concentraciones plasmáticas de vancomicina y el cálculo del índice ABC24/CIM (área bajo la curva de concentración-tiempo durante un período de 24 horas/concentración inhibitoria mínima).  Objetivos: Determinar el porcentaje de pacientes con concentraciones plasmáticas valle fuera del rango terapéutico descrito en la literatura y la dosis que sería necesaria para obtener un ABC24/CIM &#8805;400.  Resultados:  Se realizaron 36 solicitudes de monitorización de vancomicina en 31 pacientes. El 78% de las concentraciones plasmáticas determinadas estaban fuera del rango terapéutico y sólo en 8 pacientes se obtuvo un ABC24/CIM &#8805;400.  Conclusiones:  Este estudio fue el primer paso para implementar la farmacocinética clínica en la institución y evidenció la importancia de la monitorización terapéutica y la individualización de la dosis. En pacientes críticos y con un aclaramiento de creatinina elevado se necesitarían dosis mayores a las utilizadas en este estudio.]]></p></abstract>
<abstract abstract-type="short" xml:lang="en"><p><![CDATA[SUMMARY  Introduction:  Monitoring plasma concentrations of antimicrobials used to treat infections in critically ill patients is one of the strategies proposed to improve clinical results. Vancomycin monitoring reduces the risk of bacterial resistance and nephrotoxicity related to high plasma concentrations. The study was carried out in a public hospital in the province of Córdoba, Argentina, which contains 43 critical patient care units. Although the indication for vancomycin is frequent, the request for plasma levels of drugs is unusual.  Method:  The Pharmacy Service carried out a prospective pilot study for 14 weeks, implementing the monitoring of plasma vancomycin concentrations and the calculation of the ABC24/MIC index (area under the concentration-time curve over a 24-hour period/inhibitory concentration minimum).  Objectives:  To determine the percentage of patients with trough plasma concentrations outside the therapeutic range described in the literature and the dose that would be necessary to obtain an ABC24/CIM &#8805;400.  Results:  36 requests for vancomycin monitoring were made in 31 patients. 78% of the determined plasma concentrations were outside the therapeutic range and only in 8 patients was an ABC24/CIM &#8805;400 obtained.  Conclusions:  This study was the first step to implement clinical pharmacokinetics in the institution and showed the importance of therapeutic monitoring and dose individualization. In critically ill patients with high creatinine clearance, higher doses than those used in this study would be required.]]></p></abstract>
<kwd-group>
<kwd lng="es"><![CDATA[Vancomicina]]></kwd>
<kwd lng="es"><![CDATA[farmacocinética]]></kwd>
<kwd lng="es"><![CDATA[unidad de cuidados intensivos]]></kwd>
<kwd lng="es"><![CDATA[monitorización de fármacos]]></kwd>
<kwd lng="en"><![CDATA[Vancomycin]]></kwd>
<kwd lng="en"><![CDATA[pharmacokinetics]]></kwd>
<kwd lng="en"><![CDATA[intensive care unit]]></kwd>
<kwd lng="en"><![CDATA[drug monitoring]]></kwd>
</kwd-group>
</article-meta>
</front><back>
<ref-list>
<ref id="B1">
<nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Schilling]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Neuner]]></surname>
<given-names><![CDATA[E]]></given-names>
</name>
<name>
<surname><![CDATA[Rehm]]></surname>
<given-names><![CDATA[SJ.]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Vancomycin: A 50-something-yearold antibiotic we still don&#8217;t understand]]></article-title>
<source><![CDATA[Cleveland Clinic Journal of Medicine]]></source>
<year>2011</year>
<volume>78</volume>
<numero>7</numero>
<issue>7</issue>
<page-range>465-71</page-range></nlm-citation>
</ref>
<ref id="B2">
<nlm-citation citation-type="">
<collab>Drugbank.ca</collab>
<source><![CDATA[Vancomycin. DrugBank]]></source>
<year>2019</year>
</nlm-citation>
</ref>
<ref id="B3">
<nlm-citation citation-type="">
<collab>National Center for Biotechnology Information</collab>
<source><![CDATA[PubChem Database. Vancomycin, CID=14969]]></source>
<year>2019</year>
</nlm-citation>
</ref>
<ref id="B4">
<nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Revilla Cuesta]]></surname>
<given-names><![CDATA[N]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Análisis farmacocinético-farmacodinámico de vancomicina en pacientes de UCI]]></article-title>
<source><![CDATA[Universidad de Salamanca]]></source>
<year>2009</year>
</nlm-citation>
</ref>
<ref id="B5">
<nlm-citation citation-type="book">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Patel]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
<name>
<surname><![CDATA[Preuss]]></surname>
<given-names><![CDATA[CV]]></given-names>
</name>
<name>
<surname><![CDATA[Bernice]]></surname>
<given-names><![CDATA[F]]></given-names>
</name>
</person-group>
<source><![CDATA[Vancomycin]]></source>
<year>2020</year>
<publisher-loc><![CDATA[Treasure Island (FL) ]]></publisher-loc>
<publisher-name><![CDATA[StatPearls Publishing]]></publisher-name>
</nlm-citation>
</ref>
<ref id="B6">
<nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Rybak]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Lomaestro]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
<name>
<surname><![CDATA[Rotschafer]]></surname>
<given-names><![CDATA[J.]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Therapeutic monitoring of vancomycin in adult patients: A consensus review of the American Society of Health-System Pharmacists, the Infectious Diseases Society of America, and the Society of Infectious Diseases Pharmacist]]></article-title>
<source><![CDATA[Am J Health-Syst Pharm]]></source>
<year>2009</year>
<volume>66</volume>
<numero>1</numero>
<issue>1</issue>
<page-range>82-98</page-range></nlm-citation>
</ref>
<ref id="B7">
<nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Villena]]></surname>
<given-names><![CDATA[R]]></given-names>
</name>
<name>
<surname><![CDATA[González Claudio]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Nalegach]]></surname>
<given-names><![CDATA[M.E]]></given-names>
</name>
<name>
<surname><![CDATA[Vásquez]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Villareal]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Drago]]></surname>
<given-names><![CDATA[M.]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Monitoreo terapéutico de vancomicina intravenosa en una unidad de paciente crítico pediátrico]]></article-title>
<source><![CDATA[Revista Chilena de Infectología]]></source>
<year>2014</year>
<volume>31</volume>
<numero>3</numero>
<issue>3</issue>
<page-range>249-53</page-range></nlm-citation>
</ref>
<ref id="B8">
<nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Pérez]]></surname>
<given-names><![CDATA[C]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Medición de niveles plasmáticos]]></article-title>
<source><![CDATA[Revista Chilena de Infectología]]></source>
<year>2002</year>
<volume>19</volume>
<numero>1</numero>
<issue>1</issue>
</nlm-citation>
</ref>
<ref id="B9">
<nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Obara]]></surname>
<given-names><![CDATA[V]]></given-names>
</name>
<name>
<surname><![CDATA[Zacas]]></surname>
<given-names><![CDATA[C]]></given-names>
</name>
<name>
<surname><![CDATA[Carrilho]]></surname>
<given-names><![CDATA[C]]></given-names>
</name>
<name>
<surname><![CDATA[Delfino]]></surname>
<given-names><![CDATA[V]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Currently used dosage regimens of vancomycin fail to achieve therapeutic levels in approximately 40% of intensive care unit patients]]></article-title>
<source><![CDATA[Rev Bras Ter Intensiva]]></source>
<year>2016</year>
<volume>28</volume>
<numero>4</numero>
<issue>4</issue>
<page-range>380-6</page-range></nlm-citation>
</ref>
<ref id="B10">
<nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Sanchez]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Osuna]]></surname>
<given-names><![CDATA[C]]></given-names>
</name>
<name>
<surname><![CDATA[di Libero]]></surname>
<given-names><![CDATA[E]]></given-names>
</name>
<name>
<surname><![CDATA[Naninni]]></surname>
<given-names><![CDATA[E.]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Cuadernillos de Formación Médica Continua. Vancomicina]]></article-title>
<source><![CDATA[Numero V. Buenos Aires: SADI]]></source>
<year>2015</year>
</nlm-citation>
</ref>
<ref id="B11">
<nlm-citation citation-type="">
<collab>S.E.F.H</collab>
<source><![CDATA[Recomendaciones de la S.E.F.H. sobre Farmacocinética Clínica]]></source>
<year>1997</year>
</nlm-citation>
</ref>
<ref id="B12">
<nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Álvarez-Lerma]]></surname>
<given-names><![CDATA[F]]></given-names>
</name>
<name>
<surname><![CDATA[Olaechea]]></surname>
<given-names><![CDATA[P]]></given-names>
</name>
<name>
<surname><![CDATA[Grau]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
<name>
<surname><![CDATA[Marín]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Domínguez]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Martínez-Lanao]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Recomendaciones para la monitorización de antibióticos en pacientes críticos ingresados en UCI]]></article-title>
<source><![CDATA[Enfermedades Infecciosas y Microbiología Clínica]]></source>
<year>2008</year>
<volume>26</volume>
<numero>4</numero>
<issue>4</issue>
<page-range>230-9</page-range></nlm-citation>
</ref>
<ref id="B13">
<nlm-citation citation-type="">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Elyasi]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
<name>
<surname><![CDATA[Khalili]]></surname>
<given-names><![CDATA[H]]></given-names>
</name>
<name>
<surname><![CDATA[Dashti-Khavidaki]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
<name>
<surname><![CDATA[Mohammadpour]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Vancomycin-induced nephrotoxicity: mechanism, incidence, risk factors and special populations. A literature review]]></article-title>
<source><![CDATA[]]></source>
<year>2012</year>
<volume>68</volume>
<numero>9</numero>
<issue>9</issue>
<page-range>1243-55</page-range></nlm-citation>
</ref>
<ref id="B14">
<nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Van Hal]]></surname>
<given-names><![CDATA[SJ]]></given-names>
</name>
<name>
<surname><![CDATA[Paterson]]></surname>
<given-names><![CDATA[DL]]></given-names>
</name>
<name>
<surname><![CDATA[Lodise]]></surname>
<given-names><![CDATA[TP]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Systematic review and meta-analysis of vancomycin-induced nephrotoxicity associated with dosing schedules that maintain troughs between 15 and 20 milligrams per liter. Antimicrobial agents and chemotherapy]]></article-title>
<source><![CDATA[American Society for Microbiology]]></source>
<year>2013</year>
<volume>57</volume>
<numero>2</numero>
<issue>2</issue>
<page-range>734-44</page-range></nlm-citation>
</ref>
<ref id="B15">
<nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Zamoner]]></surname>
<given-names><![CDATA[W]]></given-names>
</name>
<name>
<surname><![CDATA[Prado]]></surname>
<given-names><![CDATA[IRS]]></given-names>
</name>
<name>
<surname><![CDATA[Balbi]]></surname>
<given-names><![CDATA[AL]]></given-names>
</name>
<name>
<surname><![CDATA[Ponce]]></surname>
<given-names><![CDATA[D.]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Vancomycin dosing, monitoring and toxicity: Critical review of the clinical practice]]></article-title>
<source><![CDATA[Clinical and Experimental Pharmacology and Physiology]]></source>
<year>2019</year>
<volume>46</volume>
<numero>4</numero>
<issue>4</issue>
<page-range>292-301</page-range></nlm-citation>
</ref>
<ref id="B16">
<nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Monteiro]]></surname>
<given-names><![CDATA[JF]]></given-names>
</name>
<name>
<surname><![CDATA[Hahn]]></surname>
<given-names><![CDATA[SR]]></given-names>
</name>
<name>
<surname><![CDATA[Gonçalves]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
<name>
<surname><![CDATA[Fresco]]></surname>
<given-names><![CDATA[P.]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Vancomycin therapeutic drug monitoring and population pharmacokinetic models in special patient subpopulations]]></article-title>
<source><![CDATA[Pharmacology research &amp; perspectives]]></source>
<year>2018</year>
<volume>6</volume>
<numero>4</numero>
<issue>4</issue>
</nlm-citation>
</ref>
<ref id="B17">
<nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Lin]]></surname>
<given-names><![CDATA[Z]]></given-names>
</name>
<name>
<surname><![CDATA[Jianq]]></surname>
<given-names><![CDATA[Z]]></given-names>
</name>
<name>
<surname><![CDATA[Chen]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
<name>
<surname><![CDATA[Ouyanq]]></surname>
<given-names><![CDATA[B]]></given-names>
</name>
<name>
<surname><![CDATA[Chen]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Wan]]></surname>
<given-names><![CDATA[X]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Clinical research for trough value of serum vancomycin in critical patients]]></article-title>
<source><![CDATA[Zhonghua Wei Zhong Bing Ji Jiu Yi Xue]]></source>
<year>2014</year>
<volume>26</volume>
<numero>7</numero>
<issue>7</issue>
<page-range>473-7</page-range></nlm-citation>
</ref>
<ref id="B18">
<nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Escobar]]></surname>
<given-names><![CDATA[L]]></given-names>
</name>
<name>
<surname><![CDATA[Gai]]></surname>
<given-names><![CDATA[MN.]]></given-names>
</name>
<name>
<surname><![CDATA[Regueira]]></surname>
<given-names><![CDATA[T]]></given-names>
</name>
<name>
<surname><![CDATA[Andresen]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Consideraciones farmacocinéticas en el paciente crítico]]></article-title>
<source><![CDATA[Revista médica de Chile]]></source>
<year>2012</year>
<volume>140</volume>
<numero>6</numero>
<issue>6</issue>
<page-range>780-8</page-range></nlm-citation>
</ref>
<ref id="B19">
<nlm-citation citation-type="book">
<source><![CDATA[Organización de la atención de la salud de la Provincia de Córdoba según el riesgo de las patologías y la complejidad de los efectores]]></source>
<year>1997</year>
<publisher-loc><![CDATA[Provincia de Córdoba, República Argentina ]]></publisher-loc>
<publisher-name><![CDATA[Ministerio de Salud y Seguridad Social]]></publisher-name>
</nlm-citation>
</ref>
<ref id="B20">
<nlm-citation citation-type="journal">
<article-title xml:lang=""><![CDATA[Creatinina]]></article-title>
<source><![CDATA[Es.wikipedia.org]]></source>
<year></year>
</nlm-citation>
</ref>
<ref id="B21">
<nlm-citation citation-type="book">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Levey]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Coresh]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
<name>
<surname><![CDATA[Bolton]]></surname>
<given-names><![CDATA[K]]></given-names>
</name>
<name>
<surname><![CDATA[Culleton]]></surname>
<given-names><![CDATA[B]]></given-names>
</name>
<name>
<surname><![CDATA[Harvey]]></surname>
<given-names><![CDATA[K]]></given-names>
</name>
<name>
<surname><![CDATA[Ikizler]]></surname>
<given-names><![CDATA[T]]></given-names>
</name>
</person-group>
<source><![CDATA[K/DOQI clinical practice guidelines for chronic kidney disease: Evaluation, classification, and stratification]]></source>
<year>2020</year>
<publisher-name><![CDATA[Experts@Minnes]]></publisher-name>
</nlm-citation>
</ref>
<ref id="B22">
<nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Kishk]]></surname>
<given-names><![CDATA[O]]></given-names>
</name>
<name>
<surname><![CDATA[Lardieri]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Heil]]></surname>
<given-names><![CDATA[E]]></given-names>
</name>
<name>
<surname><![CDATA[Morgan]]></surname>
<given-names><![CDATA[J.]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Vancomycin AUC/MIC and Corresponding Troughs in a Pediatric Population]]></article-title>
<source><![CDATA[The Journal of Pediatric Pharmacology and Therapeutics]]></source>
<year>2017</year>
<volume>22</volume>
<numero>1</numero>
<issue>1</issue>
<page-range>41-7</page-range></nlm-citation>
</ref>
<ref id="B23">
<nlm-citation citation-type="book">
<collab>Pharmacy Department Policies and Procedures</collab>
<source><![CDATA[SHC Vancomycin Dosing Guide [Internet]. 9/2018 ed]]></source>
<year>2018</year>
<publisher-name><![CDATA[Stanford Health Care]]></publisher-name>
</nlm-citation>
</ref>
<ref id="B24">
<nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Jin]]></surname>
<given-names><![CDATA[SJ]]></given-names>
</name>
<name>
<surname><![CDATA[Yoon]]></surname>
<given-names><![CDATA[JH]]></given-names>
</name>
<name>
<surname><![CDATA[Ahn]]></surname>
<given-names><![CDATA[BS]]></given-names>
</name>
<name>
<surname><![CDATA[Chung]]></surname>
<given-names><![CDATA[JA]]></given-names>
</name>
<name>
<surname><![CDATA[Song]]></surname>
<given-names><![CDATA[YG]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Underestimation of the calculated area under the concentration-time curve based on serum creatinine for vancomycin dosing]]></article-title>
<source><![CDATA[Infection &amp; chemotherapy]]></source>
<year>2014</year>
<volume>46</volume>
<numero>1</numero>
<issue>1</issue>
<page-range>21-9</page-range></nlm-citation>
</ref>
<ref id="B25">
<nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Cockcroft]]></surname>
<given-names><![CDATA[DW]]></given-names>
</name>
<name>
<surname><![CDATA[Gault]]></surname>
<given-names><![CDATA[MH]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Prediction of Creatinine clearance from serum creatinine]]></article-title>
<source><![CDATA[Nephron]]></source>
<year>1976</year>
<volume>16</volume>
<page-range>31-41</page-range></nlm-citation>
</ref>
<ref id="B26">
<nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Moise-Broder]]></surname>
<given-names><![CDATA[PA]]></given-names>
</name>
<name>
<surname><![CDATA[Forrest]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Birmingham]]></surname>
<given-names><![CDATA[MC.]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Pharmacodynamics of Vancomycin and Other Antimicrobials in Patients with Staphylococcus aureus Lower Respiratory Tract Infections]]></article-title>
<source><![CDATA[Clin Pharmacokinet]]></source>
<year>2004</year>
<volume>43</volume>
<page-range>925-42</page-range></nlm-citation>
</ref>
<ref id="B27">
<nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Yap]]></surname>
<given-names><![CDATA[FHY]]></given-names>
</name>
<name>
<surname><![CDATA[Joynt]]></surname>
<given-names><![CDATA[GM]]></given-names>
</name>
<name>
<surname><![CDATA[Buckley]]></surname>
<given-names><![CDATA[TA]]></given-names>
</name>
<name>
<surname><![CDATA[Wong]]></surname>
<given-names><![CDATA[ELY.]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Association of Serum Albumin Concentration and Mortality Risk in Critically Ill Patients]]></article-title>
<source><![CDATA[Anaesthesia and Intensive Care]]></source>
<year>2002</year>
<volume>30</volume>
<numero>2</numero>
<issue>2</issue>
<page-range>202-7</page-range></nlm-citation>
</ref>
<ref id="B28">
<nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Tkachuk]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
<name>
<surname><![CDATA[Collins]]></surname>
<given-names><![CDATA[K]]></given-names>
</name>
<name>
<surname><![CDATA[Ensom]]></surname>
<given-names><![CDATA[MHH]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[The Relationship Between Vancomycin Trough Concentrations and AUC/MIC Ratios in Pediatric Patients: A Qualitative Systematic Review]]></article-title>
<source><![CDATA[Pediatr Drugs]]></source>
<year>2018</year>
<volume>20</volume>
<page-range>153-64</page-range></nlm-citation>
</ref>
<ref id="B29">
<nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Del Mar Fernández de Gatta Garcia]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Revilla]]></surname>
<given-names><![CDATA[N]]></given-names>
</name>
<name>
<surname><![CDATA[Calvo]]></surname>
<given-names><![CDATA[MV]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Pharmacokinetic/pharmacodynamic analysis of vancomycin in ICU patients]]></article-title>
<source><![CDATA[Intensive Care Med]]></source>
<year>2007</year>
<volume>33</volume>
<page-range>279-85</page-range></nlm-citation>
</ref>
<ref id="B30">
<nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Tsai]]></surname>
<given-names><![CDATA[D]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Optimised dosing of vancomycin in critically ill Indigenous Australian patients with severe sepsis]]></article-title>
<source><![CDATA[Anaesthesia and intensive care]]></source>
<year>2018</year>
<volume>46</volume>
<numero>4</numero>
<issue>4</issue>
<page-range>374-80</page-range></nlm-citation>
</ref>
</ref-list>
</back>
</article>
